September 2016. Volume 12. Number 3

Low-dose hydrocortisone improves survival without bronchopulmonary dysplasia in extremely preterm infants

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016;387:1827-36.

Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 28/08/2016
Acceptance date: 30/08/2016
Publication date: 07/09/2016

Abstract

Authors´ conclusions: low dose of hydrocortisone initiated within the first 24 hours of life and continued for ten days increased the frequency of bronchopulmonary dysplasia-free survival in this high-risk population, and was associated with early extubation and a reduced need for patent ductus arteriosus ligation. No significant difference was reported in other clinically important outcomes between groups in the study population as a whole.

Reviewers´ commentary: low dose of systemic hydrocortisone discretely increases survival without DBP. However, it is necessary to extend the available data on the safety of this scheme before recommending their widespread use.

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. La hidrocortisona posnatal a dosis bajas mejora la supervivencia sin displasia broncopulmonar en prematuros extremos. Evid Pediatra. 2016;12:46.

AVC | Critically appraised articles

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016;387:1827-36.

Reviewers: Ochoa Sangrador C1, Andrés de Llano JM2.
1Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
2Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
Correspondence: Carlos Ochoa Sangrador. Email: cochoas2@gmail.com
Reception date: 28/08/2016
Acceptance date: 30/08/2016
Publication date: 07/09/2016

How to cite this article

Ochoa Sangrador C, Andrés de Llano JM. La hidrocortisona posnatal a dosis bajas mejora la supervivencia sin displasia broncopulmonar en prematuros extremos. Evid Pediatra. 2016;12:46.

References

  1. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-57.
  2. Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146:632-37.
  3. Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology. 2007;91:217-21.
  4. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2012;5:CD002057.
07/09/2016

Linked Comment